The growth and potential of human antiviral monoclonal antibody therapeutics

Nature Biotechnology

Volumn 25, Issue 12, 2007, Pages 1421-1434

  Marasco, Wayne A ^a   Sui, Jianhua ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EFFECTOR FUNCTIONS; PROPHYLAXIS; VIRAL INFECTIONS;

BIOMEDICAL ENGINEERING; CELLS; GROWTH KINETICS; HUMAN ENGINEERING; VIRUSES;

MONOCLONAL ANTIBODIES;

ANTISERUM; BAVITUXIMAB; BAYGAM; BAYRAB; CIVACIR; CR 3014; CR 3022; CR 4098; CR 4374; CR 57; CYTOMEGALOVIRUS ANTIBODY; HCMV 37; HE 16; HEPAGAM; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; HEPEX C; HERPES ZOSTER IMMUNOGLOBULIN; HGS 004; HGS 101; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNOGLOBULIN; HUMAX HEPC; HYPERRAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; KD 247; MONOCLONAL ANTIBODY; MOTAVIZUMAB; NABIHB; PALIVIZUMAB; PRO 140; RABIES IMMUNOGLOBULIN; RABIES VACCINE; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RITUXIMAB; TARVACIN; TI 57; TNX 355; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA ANTIBODY; VIGIV; VIRUS ANTIBODY; VIVAGLOBIN;

ANTIGENIC VARIATION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG HALF LIFE; ENCEPHALITIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LABORATORY; LASSA FEVER; LOWER RESPIRATORY TRACT INFECTION; LYMPHOPROLIFERATIVE DISEASE; MEASLES; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RABIES; REVIEW; RUBELLA; VACCINIA; VIRUS INFECTION; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG INDUSTRY; FORECASTING; HUMANS; VIRUS DISEASES;

EID: 36849087921     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1363     Document Type: Review

References (160)

1. Casadevall, A. & Scharff, M.D. Return to the past: the case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21, 150-161 (1995).
2. Good, R.A. & Lorenz, E. Historic aspects of intravenous immunoglobulin therapy. Cancer 68, 1415-1421 (1991).
3. Hemming, V.G. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin. Diagn. Lab. Immunol. 8, 859-863 (2001).
4. Keller, M.A. & Stiehm, E.R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13, 602-614 (2000).
5. Casadevall, A., Dadachova, E. & Pirofski, L.A. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2, 695-703 (2004).
6. Carter, P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343-357 (2006).
7. Hoogenboom, H.R. Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 23, 1105-1116 (2005).
8. Ho, M., Nagata, S. & Pastan, I. Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc. Natl. Acad. Sci. USA 103, 9637-9642 (2006).
9. Bowley, D.R., Labrijn, A.F., Zwick, M.B. & Burton, D.R. Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. Protein Eng. Des. Sel. 20, 81-90 (2007).
10. Sloan, S.E. et al. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 25, 2800-2810 (2007).
11. Coughlin, M. et al. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 361, 93-102 (2007).
12. Greenough, T.C. et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J. Infect. Dis. 191, 507-514 (2005).
13. Bernasconi, N.L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202 (2002).
14. Traggiai, E. et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10, 871-875 (2004).
15. Simmons, C.P. et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 4, e178 (2007).
16. Lanzavecchia, A. et al. Understanding and making use of human memory B cells. Immunol. Rev. 211, 303-309 (2006).
17. Kashmiri, S.V., De Pascalis, R., Gonzales, N.R. & Schlom, J. SDR grafting - a new approach to antibody humanization. Methods 36, 25-34 (2005).
18. Reading, S.A. & Dimmock, N.J. Neutralization of animal virus infectivity by antibody. Arch. Virol. 152, 1047-1059 (2007).
19. Klasse, P.J. & Sattentau, Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83, 2091-2108 (2002).
20. Klasse, P.J. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology published online, doi:10.1016/j.virol.2007.06.044 (7 September 2007).
21. Burton, D.R., Saphire, E.O. & Parren, P.W. A model for neutralization of viruses based on antibody coating of the virion surface. Curr. Top. Microbiol. Immunol. 260, 109-143 (2001).
22. Parren, P.W. & Burton, D.R. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77, 195-262 (2001).
23. Burton, D.R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2, 706-713 (2002).
24. Dimitrov, D.S. Virus entry: molecular mechanisms and biomedical applications. Nat. Rev. Microbiol. 2, 109-122 (2004).
25. Harrison, S.C. Mechanism of membrane fusion by viral envelope proteins. Adv. Virus Res. 64, 231-261 (2005).
26. Smith, A.E. & Helenius, A. How viruses enter animal cells. Science 304, 237-242 (2004).
27. Earp, L.J., Delos, S.E., Park, H.E. & White, J.M. The many mechanisms of viral membrane fusion proteins. Curr. Top. Microbiol. Immunol. 285, 25-66 (2005).
28. Skehel, J.J. & Wiley, D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
29. Imai, M., Sugimoto, K., Okazaki, K. & Kida, H. Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin. Virus Res. 53, 129-139 (1998).
30. Outlaw, M.C. & Dimmock, N.J. IgG neutralization of type A influenza viruses and the inhibition of the endosomal fusion stage of the infectious pathway in BHK cells. Virology 195, 413-421 (1993).
31. Burton, D.R. et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233-236 (2004).
32. Zwick, M.B. et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79, 1252-1261 (2005).
33. Zwick, M.B. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892-10905 (2001).
34. Webster, R.G. & Laver, W.G. Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. J. Immunol. 99, 49-55 (1967).
35. Bregenholt, S., Jensen, A., Lantto, J., Hyldig, S. & Haurum, J.S. Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections. Curr. Pharm. Des. 12, 2007-2015 (2006).
36. Pierson, T.C. et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1, 135-145 (2007).
37. Klasse, P.J. & Burton, D.R. Antibodies to West Nile virus: a double-edged sword. Cell Host Microbe 1, 87-89 (2007).
38. Hangartner, L., Zinkernagel, R.M. & Hengartner, H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat. Rev. Immunol. 6, 231-243 (2006).
39. Mehlhop, E. & Diamond, M.S. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J. Exp. Med. 203, 1371-1381 (2006).
40. Hessell, A.J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007).
41. La, S., Kim, E. & Kwon, B. In vivo ligation of glucocorticoid-induced TNF receptor enhances the T-cell immunity to herpes simplex virus type 1. Exp. Mol. Med. 37, 193-198 (2005).
42. Mills, K.H. Regulatory T cells: friend or foe in immunity to infection? Nat. Rev. Immunol. 4, 841-855 (2004).
43. Belkaid, Y. & Rouse, B.T. Natural regulatory T cells in infectious disease. Nat. Immunol. 6, 353-360 (2005).
44. Freeman, G.J., Wherry, E.J., Ahmed, R. & Sharpe, A.H. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203, 2223-2227 (2006).
45. + T cell survival in HIV infection. J. Exp. Med. 203, 2281-2292 (2006).
46. Day, C.L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354 (2006).
47. + T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198-1202 (2006).
48. Barber, D.L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
49. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8, 1246-1254 (2007).
50. Strand, V., Kimberly, R. & Isaacs, J.D. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov. 6, 75-92 (2007).
51. Farzaneh, L., Kasahara, N. & Farzaneh, F. The strange case of TGN1412. Cancer Immunol. Immunother. 56, 129-134 (2007).
52. Simoes, E.A. et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J. Pediatr. 151, 34-42 (2007).
53. Wu, H. et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368, 652-665 (2007).
54. MedImmune. MedImmune's Motavizumab reduced RSV hospitalizations by 83 percent among high-risk Native American, full-term infants in placebo-controlled Phase 3 study. Medimmune Press Release 〈http://phx.corporate-ir. net/phoenix.zhtml?c=83037&p=irol-investornewsArticle&ID= 1043517&highlight=motavizumab〉 (2007).
55. Oswald, W.B. et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3, e9 (2007).
56. Bakker, A.B. et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol. 79, 9062-9068 (2005).
57. de Kruif, J. et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu. Rev. Med. 58, 359-368 (2007).
58. Goudsmit, J. et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J. Infect. Dis. 193, 796-801 (2006).
59. Morrey, J.D. et al. Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J. Infect. Dis. 194, 1300-1308 (2006).
60. Zhu, Z. et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. USA 104, 12123-12128 (2007).
61. Engle, M.J. & Diamond, M.S. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J. Virol. 77, 12941-12949 (2003).
62. Sui, J. et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. USA 101, 2536-2541 (2004).
63. Parren, P.W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
64. Sui, J. et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J. Virol. 79, 5900-5906 (2005).
65. Kretzschmar, M., van den Hof, S., Wallinga, J. & van Wijngaarden, J. Ring vaccination and smallpox control. Emerg. Infect. Dis. 10, 832-841 (2004).
66. Pourbohloul, B. et al. Modeling control strategies of respiratory pathogens. Emerg. Infect. Dis. 11, 1249-1256 (2005).
67. McLean, A.R., May, R.M., Pattison, J. & Weiss, R.A., eds. SARS A Case Study in Emerging Infections (Oxford University Press, New York, 2005).
68. Doblas, A. et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J. Clin. Virol. 36, 156-158 (2006).
69. Haaheim, L.R. Original antigenic sin. A confounding issue? Dev. Biol. (Basel) 115, 49-53 (2003).
70. Li, H. et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 24, 210-215 (2006).
71. Yamane-Ohnuki, N. et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87, 614-622 (2004).
72. Lazar, G.A. et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103, 4005-4010 (2006).
73. Shields, R.L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733-26740 (2002).
74. Umana, P., Jean-Mairet, J., Moudry, R., Amstutz, H. & Bailey, J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176-180 (1999).
75. Goncalvez, A.P., Engle, R.E., St Claire, M., Purcell, R.H. & Lai, C.J. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. USA 104, 9422-9427 (2007).
76. Shultz, L.D., Ishikawa, F. & Greiner, D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7, 118-130 (2007).
77. Burton, D.R. & Wilson, I.A. Immunology. Square-dancing antibodies. Science 317, 1507-1508 (2007).
78. van der Neut Kolfschoten, M. et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554-1557 (2007).
79. Radoshitzky, S.R. et al. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 446, 92-96 (2007).
80. Evans, M.J. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801-805 (2007).
81. Glass, W.G. et al. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202, 1087-1098 (2005).
82. Glass, W.G. et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203, 35-40 (2006).
83. Brekke, O.H. & Sandlie, I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2, 52-62 (2003).
84. Reichert, J.M. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 21, 1-7 (2007).
85. Wurm, F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22, 1393-1398 (2004).
86. Ko, K. & Koprowski, H. Plant biopharming of monoclonal antibodies. Virus Res. 111, 93-100 (2005).
87. Sivakumar, G. Bioreactor technology: a novel industrial tool for high-tech production of bioactive molecules and biopharmaceuticals from plant roots. Biotechnol. J. 1, 1419-1427 (2006).
88. Nimmerjahn, F. & Ravetch, J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510-1512 (2005).
89. Kaneko, Y., Nimmerjahn, F. & Ravetch, J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
90. Burton, D.R. & Dwek, R.A. Immunology. Sugar determines antibody activity. Science 313, 627-628 (2006).
91. Morens, D.M., Halstead, S.B. & Marchette, N.J. Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb. Pathog. 3, 231-237 (1987).
92. Littaua, R., Kurane, I. & Ennis, F.A. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J. Immunol. 144, 3183-3186 (1990).
93. Halstead, S.B. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140, 527-533 (1979).
94. Roehrig, J.T., Bolin, R.A. & Kelly, R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246, 317-328 (1998).
95. Heinz, F.X. Epitope mapping of flavivirus glycoproteins. Adv. Virus Res. 31, 103-168 (1986).
96. Richardson, D. & Conner, H. Immunization against measles. J. Am. Med. Assoc. 72, 1046-1048 (1919).
97. Luke, T.C., Kilbane, E.M., Jackson, J.L. & Hoffman, S.L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann. Intern. Med. 145, 599-609 (2006).
98. Stoll, H.F. Value of convalesent blood and serum in treatment of influenzal pneumonia. J. Am. Med. Assoc. 73, 478-483 (1919).
99. Weech, A. The prophylaxis of varicella with convalescents serum. J. Am. Med. Assoc. 82, 1245-1246 (1924).
100. Stinebaugh, B.J. et al. Bolivian hemorrhagic fever. A report of four cases. Am. J. Med. 40, 217-230 (1966).
101. Ruggiero, H.A. et al. Presse Med. Treatment of Argentine hemorrhagic fever with convalescents plasma. 4433 cases. 15, 2239-2242 (1986).
102. Maiztegui, J.I., Fernandez, N.J. & de Damilano, A.J. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2, 1216-1217 (1979).
103. Leifer, E., Gocke, D.J. & Bourne, H. Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am. J. Trop. Med. Hyg. 19, 677-679 (1970).
104. Frame, J.D., Verbrugge, G.P., Gill, R.G. & Pinneo, L. The use of Lassa fever convalescent plasma in Nigeria. Trans. R. Soc. Trop. Med. Hyg. 78, 319-324 (1984).
105. Mupapa, K. et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J. Infect. Dis. 179 (Suppl. 1), S18-S23 (1999).
106. Jacobson, J.M. et al. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J. Infect. Dis. 168, 298-305 (1993).
107. Vittecoq, D. et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc. Natl. Acad. Sci. USA 92, 1195-1199 (1995).
108. Guay, L.A. et al. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS 16, 1391-1400 (2002).
109. Wong, V.W., Dai, D., Wu, A.K. & Sung, J.J. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med. J. 9, 199-201 (2003).
110. Zhou, B., Zhong, N. & Guan, Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N. Engl. J. Med. 357, 1450-1451 (2007).
111. Mansbach, J., Kunz, S., Acholonu, U., Clark, S. & Camargo, C.A., Jr. Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis. Pediatr. Emerg. Care 23, 362-367 (2007).
112. Mejias, A. et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob. Agents Chemother. 49, 4700-4707 (2005).
113. Oliphant, T. et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11, 522-530 (2005).
114. Throsby, M. et al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J. Virol. 80, 6982-6992 (2006).
115. van den Brink, E.N. et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J. Virol. 79, 1635-1644 (2005).
116. ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 3, e237 (2006).
117. Arizono, H. et al. Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys. Arzneimittelforschung 44, 909-913 (1994).
118. Tempest, P.R., White, P., Buttle, M., Carr, F.J. & Harris, W.J. Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus. Int. J. Biol. Macromol. 17, 37-42 (1995).
119. Kunitomi, A., Arima, N. & Ishikawa, T. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab. Haematologica 92, e49-e52 (2007).
120. Yokoyama, T. et al. Varicella-zoster virus gH:gL contains a structure reactive with the anti-human gamma chain of IgG near the glycosylation site. J. Gen. Virol. 82, 331-334 (2001).
121. Kuritzkes, D.R. et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189, 286-291 (2004).
122. Borgia, G. HepeX-C (XTL Biopharmaceuticals). Curr. Opin. Investig. Drugs 5, 892-897 (2004).
123. Habersetzer, F. et al. Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology 249, 32-41 (1998).
124. Sejvar, J.J. et al. Long-term neurological and functional outcome in Nipah virus infection. Ann. Neurol. 62, 235-242 (2007).
125. Guttieri, M.C., Bookwalter, C. & Schmaljohn, C. Expression of a human, neutralizing monoclonal antibody specific to puumala virus G2-protein in stably-transformed insect cells. J. Immunol. Methods 246, 97-108 (2000).
126. de Carvalho Nicacio, C. et al. A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus. J. Med. Virol. 60, 446-454 (2000).
127. Koch, J., Liang, M., Queitsch, I., Kraus, A.A. & Bautz, E.K. Human recombinant neutralizing antibodies against hantaan virus G2 protein. Virology 308, 64-73 (2003).
128. Liang, M. et al. Generation of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain. J. Med. Virol. 69, 99-107 (2003).
129. Roberts, A. et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J. Infect. Dis. 193, 685-692 (2006).
130. Prabakaran, P. et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J. Biol. Chem. 281, 15829-15836 (2006).
131. Maruyama, T. et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73, 6024-6030 (1999).
132. Gould, L.H. et al. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J. Virol. 79, 14606-14613 (2005).
133. Daffis, S. et al. Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants. Virology 337, 262-272 (2005).
134. Allander, T. et al. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J. Gen. Virol. 81, 2451-2459 (2000).
135. Johansson, D.X. et al. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl. Acad. Sci. USA 104, 16269-16274 (2007).
136. Keck, Z.Y. et al. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J. Virol. 78, 7257-7263 (2004).
137. Kim, S.H. & Park, S.Y. Selection and characterization of human antibodies against hepatitis B virus surface antigen (HBsAg) by phage-display. Hybrid. Hybridomics 21, 385-392 (2002).
138. Park, S.G. et al. Hepatitis B virus-neutralizing anti-pre-S1 human antibody fragments from large naive antibody phage library. Antiviral Res. 68, 109-115 (2005).
139. Lloyd-Evans, P. & Gilmour, J.E. Expression of neutralizing recombinant human antibodies against Varicella Zoster virus for use as a potential prophylactic. Hybridoma 19, 143-149 (2000).
140. Kausmally, L. et al. Neutralizing human antibodies to varicella-zoster virus (VZV) derived from a VZV patient recombinant antibody library. J. Gen. Virol. 85, 3493-3500 (2004).
141. Hanson, B.J. et al. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir. Res. 7, 126 (2006).
142. Wyde, P.R. et al. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatr. Res. 38, 543-550 (1995).
143. Zhu, Z. et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J. Virol. 80, 891-899 (2006).
144. de Carvalho Nicacio, C. et al. Neutralizing human Fab fragments against measles virus recovered by phage display. J. Virol. 76, 251-258 (2002).
145. Gigler, A. et al. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J. Virol. 73, 1974-1979 (1999).
146. Kim, S.J. et al. Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display. Virology 318, 598-607 (2004).
147. Chen, Z. et al. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. USA 103, 1882-1887 (2006).
148. Schmaljohn, C., Cui, Y., Kerby, S., Pennock, D. & Spik, K. Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phagedisplay combinatorial library. Virology 258, 189-200 (1999).
149. Chen, Z. et al. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J. Virol. 81, 8989-8995 (2007).
150. Higo-Moriguchi, K., Akahori, Y., Iba, Y., Kurosawa, Y. & Taniguchi, K. Isolation of human monoclonal antibodies that neutralize human rotavirus. J. Virol. 78, 3325-3332 (2004).
151. Burton, D.R. et al. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134-10137 (1991).
152. Veazey, R.S. et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343-346 (2003).
153. Buchacher, A. et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10, 359-369 (1994).
154. Armbruster, C. et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J. Antimicrob. Chemother. 54, 915-920 (2004).
155. Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615-622 (2005).
156. Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642-6647 (1993).
157. Choudhry, V. et al. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363, 79-90 (2007).
158. Hadlock, K.G. et al. Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. J. Virol. 71, 5828-5840 (1997).
159. Champion, J.M. et al. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J. Immunol. Methods 235, 81-90 (2000).
160. Ando, T., Yamashiro, T., Takita-Sonoda, Y., Mannen, K. & Nishizono, A. Construction of human Fab library and isolation of monoclonal Fabs with rabies virus-neutralizing ability. Microbiol. Immunol. 49, 311-322 (2005).